Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Xylonix Pte. Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 pending office actions represent the company's current efforts to secure patent rights in the life sciences sector. The focus on Biotechnology & Pharmaceuticals indicates that the company is developing innovations in medicine or biology. Practitioners should prepare for the specific examination standards common in this technology area.
The 2 pending office actions are split across 2 distinct art units and 2 distinct examiners. This structure indicates that each pending matter is being examined independently by a different examiner in a different art unit. There is no overlap in the examination process for these 2 pending office actions, which requires a unique strategy for each case. The involvement of 2 distinct art units suggests that the company's technology is recognized across different specialized groups.
LEE, SIN J is the busiest examiner, responsible for 1 busiest examiner pending action. This represents a portion of the 2 total pending office actions in the portfolio. Since each of the 2 distinct examiners holds exactly 1 action, the workload is evenly balanced. Practitioners must coordinate across 2 distinct art units and 2 distinct examiners to manage the current 2 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, SIN J | 1 | 68.8% | +25.1% |
| BAEK, JONGHWAN NMN | 1 | 50.0% | +0.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18797689 | GAMMA-POLYGLUTAMIC ACID AND ZINC COMPOSITIONS | LEE, SIN J | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18797689 | GAMMA-POLYGLUTAMIC ACID AND ZINC COMPOSITIONS | LEE, SIN J | 1613 | §103 | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18282094 | PHARMACEUTICAL POLYMER CONJUGATES | BAEK, JONGHWAN NMN | 1618 | §103§112DP | Non-Final OA | — | Pending | Sep 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialXylonix Pte. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Sin J Lee has the most, with 1 of Xylonix Pte. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
